Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Caladrius Biosciences, Inc. (CLBS)

0.4264   -0.086 (-16.75%) 09-14 16:00
Open: 0.648 Pre. Close: 0.5122
High: 0.6497 Low: 0.382
Volume: 26,946,654 Market Cap: 0(M)

Technical analysis

as of: 2022-11-18 4:19:29 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 3.47     One year: 5.34
Support: Support1: 0.38    Support2: 0.31
Resistance: Resistance1: 2.97    Resistance2: 4.57
Pivot: 0.69
Moving Average: MA(5): 0.42     MA(20): 1.54
MA(100): 5.58     MA(250): 8.41
MACD: MACD(12,26): -1.1     Signal(9): -1.1
Stochastic oscillator: %K(14,3): 1     %D(3): 1
RSI: RSI(14): 19.9
52-week: High: 17.09  Low: 0.38
Average Vol(K): 3-Month: 6,796 (K)  10-Days: 26,947 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CLBS ] has closed above bottom band by 43.3%. Bollinger Bands are 2.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.65 - 0.65 0.65 - 0.66
Low: 0.38 - 0.38 0.38 - 0.38
Close: 0.42 - 0.43 0.43 - 0.43

Company Description

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Headline News

Wed, 23 Nov 2022
AMD To Raise Prices of Xilinx Based FPGA Products By Up To 25% Starting 2023, Reveals Internal Letter - Wccftech

Fri, 11 Nov 2022
Cass Lake-Bena Schools referendum passes by slim margin - The Bemidji Pioneer

Thu, 15 Sep 2022
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully - Simply Wall St

Wed, 14 Sep 2022
Thinking about buying stock in Caladrius Biosciences, Timber Pharmaceuticals, 89Bio, Alaunos Therapeutics - Benzinga

Wed, 14 Sep 2022
Caladrius Biosciences (CLBS) Announces Approval of Merger and Name Change to Lisata Therapeutics - StreetInsider.com

Wed, 03 Aug 2022
IRCC to anticipate add a new language test for Canada immigration - Y-Axis Solutions Private Limited

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 60 (M)
Shares Float 59 (M)
% Held by Insiders 2.7 (%)
% Held by Institutions 18.5 (%)
Shares Short 544 (K)
Shares Short P.Month 564 (K)

Stock Financials

EPS -0.53
EPS Est Next Qtl -0.77
EPS Est This Year -2.43
EPS Est Next Year -2.96
Book Value (p.s.) 1.67
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -16.8
Return on Equity (ttm) -23.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.47
Qtrly Earnings Growth 0
Operating Cash Flow -20 (M)
Levered Free Cash Flow -16 (M)

Stock Valuations

PE Ratio -0.81
PEG Ratio -0.1
Price to Book value 0.25
Price to Sales 0
Price to Cash Flow -1.29

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2016-07-27
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.